Antogen Secures Seed Financing to Advance Next-Generation Immune Surveillance Diagnostics

▤ Summary

Antogen has closed a seed financing round led by iGrow Venture Partners with support from life sciences angel investors. The company will use the capital to develop its proteomics platform, machine learning models, and proprietary biological datasets. It also plans to expand its scientific and operational capabilities as it pushes its immune surveillance diagnostics toward broader customer adoption. Antogen already has early commercial traction through contract research services, which suggests room for near-term growth. The company positions its technology for multiple clinical care settings and broader patient-care applications.

$ Funding

▦ Linked Companies